Drug Study:Hepatitis B Vaccine(Recombivax HB)


Generic Name: Hepatitis B Vaccine[RECOMBINANT](hep´a-ti-tis)
Brand Name:Engerix-B, Recombivax HB
Classifications:antiinfective; vaccine
Pregnancy Category:C





10 mcg/mL, 5 mcg/0.5 mL, 40 mcg/mL (Recombivax);  20 mcg/mL, 10 mcg/0.5 mL (Engerix-B)

Suspension of inactivated and purified hepatitis B surface antigen (HBsAg) derived from human plasma of screened asymptomatic HBsAg-positive carriers of hepatitis B virus. Hepatitis B vaccine recombinant is the first vaccine produced by gene splicing. No human plasma is used in its production.
Therapeutic effects
The recommended 3-dose regimen produces active immunity against hepatitis B infection by inducing protective antibody (anti-HBs) formation.

To promote active immunity in individuals at high risk of potential exposure to hepatitis B virus or HBsAg-positive materials. Has been used simultaneously (into different sites) with hepatitis B immune globulin (H-BIG) for post-exposure prophylaxis in selected patients and in infants born to HBsAg-positive mothers.

History of allergic reaction to hepatitis B vaccine or to any ingredient in the formulation; HBsAg carriers. Safe use during pregnancy (category C) and lactation is not established.

Cautious use
Compromised cardiopulmonary status, serious active infection or fever; thrombocytopenia or other bleeding disorders.

Route & dosage 

Hepatitis B Prophylaxis

adult: IM  Recombivax 1 mL (10 mcg) at 0, 1, and 6 mo; Engerix-B 1 mL (20 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo

child: IM  Recombivax 0.5 mL (5 mcg) at 0, 1, and 6 mo; Engerix-B 0.5 mL (10 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo

Dialysis and Immunodeficient Patients

adult: IM  Recombivax 2 mL (20 mcg) at 0, 1, and 6 mo Engerix-B 2 mL (40 mcg) at 0, 1, and 6 mo or 0, 1, 2, and 12 mo



  • Give preferably into the deltoid and in neonates into the anterolateral thigh, avoiding blood vessels and nerves. Carefully aspirate to prevent inadvertent intravascular injection.
  • Have epinephrine immediately available to treat anaphylaxis.
  • Shake vial well before withdrawing dose to assure uniform suspension.
  • Store unopened and opened vials at 2°–8° C (36°–46° F) unless otherwise directed. Avoid freezing (freezing destroys potency).

Adverse effects

BodyWhole:Mild local tenderness at injection site, local inflammatory reaction (swelling, heat, redness, induration, pain); fever, malaise, fatigue, headache, dizziness, faintness, leg cramps, myalgia, arthralgia.
GI:Nausea,vomiting, diarrhea.
Skin:Rash,urticaria, pruritus.
interaction drug:No clinically significant interactions established.

Nursing implications 

Assessment & Drug Effects

  • Note:The ACIP recommends serologic confirmation of postvaccination immunity in patients undergoing dialysis and in immunodeficient patients.
  • Monitor temperature.Some patients develop a temperature elevation of 38.3° C (101° F) following vaccination that may last 1 or 2 d.

Patient & Family Education    

  • Learn potential adverse reaction.
  • Do not breast feed while taking this drug without consulting physician.
This is a community of professional nurses gifted with literary skills who share theoretical and clinical knowledge, nursing tidbits, facts, statistics, healthcare information, news, disease data, care plans, drugs and anything under the umbrella of nursing. All information expressed here are courtesies of the respective authors. Views on topics do not generally reflect that of the entire community. Articles submitted here are original but are checked for minor typographical errors, and are formatted for site compatibility.This is a site that continuously improves and broadcasts healthcare information relevant to today's ever-changing world.


Please enter your comment!
Please enter your name here